{"id":841595,"date":"2026-10-14T16:55:04","date_gmt":"2026-10-14T16:55:04","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=841595"},"modified":"2026-10-14T16:55:04","modified_gmt":"2026-10-14T16:55:04","slug":"rett-syndrome-clinical-trial-pipeline-delveinsight-highlights-major-advances-transformative-therapies-and-20-leading-players-wheeling-the-therapeutics-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/rett-syndrome-clinical-trial-pipeline-delveinsight-highlights-major-advances-transformative-therapies-and-20-leading-players-wheeling-the-therapeutics-landscape_841595.html","title":{"rendered":"Rett Syndrome Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the Therapeutics Landscape"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791968042.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Rett Syndrome Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the Therapeutics Landscape\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791968042.jpg\" alt=\"Rett Syndrome Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the Therapeutics Landscape\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Rett Syndrome Clinical trial analysis report delivers important insights into ongoing research on 20+ pipeline Rett Syndrome drugs, clinical strategies, upcoming therapeutics, and commercial analysis.<\/div>\n<p style=\"text-align: justify;\"><strong>(Albany, US) On October 14, 2026 &#8211; <\/strong>DelveInsight&rsquo;s, &ldquo;<strong>Rett Syndrome Pipeline Insight 2026<\/strong>&rdquo; report provides comprehensive insights about <strong>20+ companies<\/strong> and <strong>22+ pipeline drugs<\/strong> in Rett Syndrome pipeline landscape. It covers the Rett Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rett Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Click here to explore the therapies and trials making headlines @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/rett-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/rett-syndrome-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Rett Syndrome Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>October 01, 2026 &ndash; Taysha Gene Therapies<\/em><\/strong> announced presentations highlighting its TSHA-102 gene therapy program for Rett syndrome. The company announced planned oral and poster presentations at the 55th Child Neurology Society Annual Meeting, scheduled for October 14&ndash;17, 2026. The presentations will cover safety and efficacy findings from the REVEAL Phase 1\/2 trial, including functional improvements observed across different age groups.<\/li>\n<li><strong><em>October 01, 2026 &ndash; UNC Health<\/em><\/strong> reported on the Embolden trial evaluating NGN-401, an investigational gene therapy for females aged three years and older with Rett syndrome. Enrollment and dosing of all 25 participants had been completed in June 2026, with topline results expected in the second half of 2027<\/li>\n<li>DelveInsight&rsquo;s Rett Syndrome Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Rett Syndrome treatment.<\/li>\n<li>The leading Rett Syndrome Companies such as <strong><em>Taysha Gene Therapies Inc., Biomed Industries Inc., ACADIA Pharmaceuticals Inc<\/em><\/strong>., and others.<\/li>\n<li>Promising Rett Syndrome Therapies such as <strong><em>Blarcamesine, TSHA-102, NGN-401, GXV 001, Cannabidivarin, AMO 04 <\/em><\/strong>and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Want to know which companies are leading innovation in Rett Syndrome? @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/rett-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Rett Syndrome Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The Rett Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Rett Syndrome Pipeline Report also highlights the unmet needs with respect to the Rett Syndrome.<\/p>\n<p style=\"text-align: justify;\"><strong>Rett Syndrome Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Rett syndrome is a rare genetic neurodevelopmental disorder that primarily affects females and is characterized by an initial period of normal growth followed by a progressive loss of motor, language, and cognitive skills. It typically begins between 6 and 18 months of age and leads to severe neurological impairment, including loss of purposeful hand movements, abnormal gait, and intellectual disability. Rett syndrome is mainly caused by mutations in the MECP2 gene located on the X chromosome, which encodes a protein essential for normal brain development and gene regulation. These mutations usually occur sporadically (de novo) rather than being inherited, and they result in either insufficient or dysfunctional protein production, disrupting normal neuronal development.<\/p>\n<p style=\"text-align: justify;\"><strong>Rett Syndrome Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>TSHA-102: Taysha Gene Therapies, Inc.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">TSHA-102 is an investigational adeno-associated virus serotype 9 (AAV9) gene therapy developed by Taysha Gene Therapies for Rett syndrome, designed to deliver a functional copy of the MECP2 gene using the company&rsquo;s miRARE&reg; platform, which enables cell-by-cell regulation of transgene expression to avoid toxicity from overexpression, its mechanism of action is therefore based on gene replacement therapy to restore MeCP2 protein function in the central nervous system, addressing the underlying genetic cause of Rett syndrome. The therapy is being developed specifically for the treatment of Rett syndrome across pediatric, adolescent, and adult patients. TSHA-102 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough Therapy designation (FDA), supporting expedited development. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Rett Syndrome.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Bionetide: Biomed Industries, Inc<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Bionetide&trade; (NA-921) is an investigational oral small-molecule drug developed by Biomed Industries, Inc. for the treatment of Rett syndrome, its mechanism of action is associated with neuroprotective and neurogenic effects, as the drug crosses the blood&ndash;brain barrier, promotes neurogenesis (generation of new neurons), and enhances neuronal function, thereby addressing neurological deficits seen in Rett syndrome. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Rett Syndrome.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ACP-2591: ACADIA Pharmaceuticals Inc.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ACP-2591 is an investigational oral small-molecule cGP (cyclic glycine-proline) analog being developed by ACADIA Pharmaceuticals Inc. for Rett syndrome and Fragile X syndrome, and its mechanism of involves modulation of IGF-1&ndash;related neurotrophic signaling pathways, thereby supporting neuronal function, synaptic activity, and brain development, which are impaired in Rett syndrome. The drug is therefore being developed specifically for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Rett Syndrome.<\/p>\n<p style=\"text-align: justify;\"><strong>The Rett Syndrome Pipeline report provides insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Rett Syndrome with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rett Syndrome Treatment.<\/li>\n<li>Rett Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Rett Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rett Syndrome market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>If you&rsquo;re tracking ongoing Rett Syndrome Clinical trials, this press release is a must-read @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/rett-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Rett Syndrome Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Rett Syndrome Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Taysha Gene Therapies Inc., Biomed Industries Inc., ACADIA Pharmaceuticals Inc<\/em><\/strong>., and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Rett Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Intra-articular<\/li>\n<li>Intraocular<\/li>\n<li>Intrathecal<\/li>\n<li>Intravenous<\/li>\n<li>Ophthalmic<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Transdermal<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Rett Syndrome Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oligonucleotide<\/li>\n<li>Peptide<\/li>\n<li>Small molecule<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Rett Syndrome Pipeline Report covers it all &ndash; check it out now @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/rett-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Rett Syndrome Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Rett Syndrome Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Rett Syndrome Companies-<strong><em>Taysha Gene Therapies Inc., Biomed Industries Inc., ACADIA Pharmaceuticals Inc<\/em><\/strong>., and others.<\/li>\n<li>Rett Syndrome Therapies-<strong><em> Fingolimod (FTY720), Bionetide, TSHA-102, NNZ-2566, NTI164, ANAVEX2-73<\/em><\/strong> and others.<\/li>\n<li>Rett Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Rett Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover what&rsquo;s next for the Rett Syndrome treatment landscape in this detailed analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/rett-syndrome-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Rett Syndrome Emerging Drugs and Major Players<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Rett Syndrome: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutics Assessment<\/li>\n<li>Rett Syndrome &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Blarcamesine: Anavex Life Sciences Corp<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>TSHA-102: Taysha GTx<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Inactive Products<\/li>\n<li>Rett Syndrome Key Companies<\/li>\n<li>Rett Syndrome Key Products<\/li>\n<li>Rett Syndrome- Unmet Needs<\/li>\n<li>Rett Syndrome- Market Drivers and Barriers<\/li>\n<li>Rett Syndrome- Future Perspectives and Conclusion<\/li>\n<li>Rett Syndrome Analyst Views<\/li>\n<li>Rett Syndrome Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=rett-syndrome-clinical-trial-pipeline-delveinsight-highlights-major-advances-transformative-therapies-and-20-leading-players-wheeling-the-therapeutics-landscape\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/rett-syndrome-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/rett-syndrome-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=rett-syndrome-clinical-trial-pipeline-delveinsight-highlights-major-advances-transformative-therapies-and-20-leading-players-wheeling-the-therapeutics-landscape\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Rett Syndrome Clinical trial analysis report delivers important insights into ongoing research on 20+ pipeline Rett Syndrome drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 14, 2026 &#8211; DelveInsight&rsquo;s, &ldquo;Rett Syndrome Pipeline Insight 2026&rdquo; report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/rett-syndrome-clinical-trial-pipeline-delveinsight-highlights-major-advances-transformative-therapies-and-20-leading-players-wheeling-the-therapeutics-landscape_841595.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-841595","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/841595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=841595"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/841595\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=841595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=841595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=841595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}